Last reviewed · How we verify
Vaxneuvance vaccine
Vaxneuvance vaccine is a Biologic drug developed by Sanofi. It is currently in Phase 3 development for Prevention of COVID-19 disease in individuals 6 months of age and older. Also known as: Vaxneuvance ™.
Vaxneuvance vaccine works by stimulating the body's immune system to produce a protective response against COVID-19.
Vaxneuvance vaccine works by stimulating the body's immune system to produce a protective response against COVID-19. Used for Prevention of COVID-19 disease in individuals 6 months of age and older.
At a glance
| Generic name | Vaxneuvance vaccine |
|---|---|
| Also known as | Vaxneuvance ™ |
| Sponsor | Sanofi |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
It does this by introducing a piece of the SARS-CoV-2 virus to the body, which triggers an immune response and helps the body build immunity against future infections.
Approved indications
- Prevention of COVID-19 disease in individuals 6 months of age and older
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
Key clinical trials
- Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008) (PHASE3)
- Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7) (PHASE3)
- V114 and Acute Otitis Media (V114-032/PNEU-ERA) (PHASE3)
- A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age (PHASE3)
- A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age (PHASE3)
- Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911) (PHASE3)
- Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15 (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vaxneuvance vaccine CI brief — competitive landscape report
- Vaxneuvance vaccine updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about Vaxneuvance vaccine
What is Vaxneuvance vaccine?
How does Vaxneuvance vaccine work?
What is Vaxneuvance vaccine used for?
Who makes Vaxneuvance vaccine?
Is Vaxneuvance vaccine also known as anything else?
What development phase is Vaxneuvance vaccine in?
What are the side effects of Vaxneuvance vaccine?
Related
- Manufacturer: Sanofi — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Prevention of COVID-19 disease in individuals 6 months of age and older
- Also known as: Vaxneuvance ™
- Compare: Vaxneuvance vaccine vs similar drugs
- Pricing: Vaxneuvance vaccine cost, discount & access